✦ LIBER ✦

Dual antiplatelet therapy: no added benefits for high-risk patients

Book ID: 120852192
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 139 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615290-00027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-181: Benefits of CD 34 Antibody Coat

TCT-181: Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Risk–Benefit Profile of Long-Term Dual-

Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet Therapy Among Patients With Ischemic Stroke

✍ Lee, Meng; Saver, Jeffrey L.; Hong, Keun-Sik; Rao, Neal M.; Wu, Yi-Ling; Ovbiage 📂 Article 📅 2013 🏛 American College of Physicians 🌐 English ⚖ 165 KB

Prolonged Dual Antiplatelet Therapy Impr

Prolonged Dual Antiplatelet Therapy Improves Clinical Outcomes in High-risk Patients Implanted with Sirolimus-eluting Stents

✍ Jia Dean; Zhou Yujie; Zhao Yingxin; Liu Yuyang; Guo Yonghe; Cheng Wanjun; Cao Zh 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

The potential benefits and risks of the

The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients

✍ Takafumi Nakagawa; Yoshikazu Hiasa; Shinobu Hosokawa; Tomoko Minami; Yudai Yano; 📂 Article 📅 2011 🏛 Elsevier 🌐 Japanese ⚖ 333 KB

S36-5 PROLONGED DUAL ANTIPLATELET THERAP

S36-5 PROLONGED DUAL ANTIPLATELET THERAPY IMPROVES CLINICAL OUTCOMES AFTER SIROLIMUS-ELUTING STENTS IMPLANTATION IN HIGH-RISK PATIENTS

✍ Dean Jia; Yujie Zhou; Yingxin Zhao; Yuyang Liu; Yonghe Guo; Wan-jun Cheng; Jian- 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Is clopidogrel the antiplatelet drug of

Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No

✍ G. J. HANKEY 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB